✦ LIBER ✦

P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®]

✍ Scribed by P. Marcellin; F. Bonino; G.K.K. Lau; P. Farci; C. Yurdaydin; T. Piratvisuth; R. Jin; S. Gurel; S. Hadziyannis; Z. Lu; M. Popescu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

743 The majority of patients with HBeAg-

✍ P. Marcellin; E. Bonino; G.K.K. Lau; P. Farci; C. Yurdaydin; T. Piratvisuth; R. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 115 KB

49 Association between HBeAg seroconvers

✍ T. Piratvisuth; G.K.K. Lau; P. Marcellin; W.C. Chow; G. Cooksley; M.W. Fried; S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

98 EXTENDED (2 YEARS) TREATMENT WITH PEG

✍ P. Lampertico; M. Vigano; G. Di Costanzo; E. Sagnelli; M. Fasano; V. Di Marco; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 52 KB

50 Durability of response and occurrence

✍ G.K.K. Lau; T. Piratvisuth; K.X. Luo; P. Marcellin; S. Thongsawat; G. Cooksley; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 253 KB

484 On-treatment predictors of sustained

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB

491 Peginterferon alpha-2a (40KD) (PEGAS

✍ G. Cooksley; G.K.K. Lau; P. Marcellin; T. Piratvisuth; E. Bonino; K.X. Luo; S. H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 251 KB